The company says it plans to submit its data to the FDA for authorization.
A booster dose of the Pfizer-BioNTech Covid-19 vaccine raised antibody levels in children ages 5 to 11, the company said Thursday.
The results are welcome news, but as scientists have seen in the omicron era, the booster may only provide short-lived protection against infection. In that report, CDC researchers said the omicron variant was the reason the shots' protection fell so low. The omicron wave led to aLess than 30 percent of children ages 5 to 11 have received two doses of a vaccine,Pfizer said it plans to submit its data to the Food and Drug Administration in the coming days for emergency use authorization. Currently, Pfizer boosters are available only to people ages 12 and up.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
Pfizer to seek COVID booster for healthy 5- to 11-year-oldsNEW: Pfizer says it wants to expand its COVID-19 booster shots to healthy elementary-age kids.
続きを読む »
Pfizer to seek COVID-19 booster for healthy 5- to 11-year-oldsPfizer said Thursday it wants to expand its COVID-19 booster shots to healthy elementary-age kids.
続きを読む »
Pfizer to seek COVID booster for healthy 5- to 11-year-oldsPfizer said Thursday it wants to expand its COVID-19 booster shots to healthy children ages 5-11.
続きを読む »
Pfizer to seek COVID booster for healthy 5- to 11-year-oldsPfizer says new data shows healthy 5- to 11-year-olds could benefit from another kid-sized shot.
続きを読む »
Pfizer to seek COVID booster for healthy 5- to 11-year-oldsPfizer says new data shows healthy 5- to 11-year-olds could benefit from another kid-sized shot.
続きを読む »
Covid booster shot bolsters protection in 5-to-11-year-olds, Pfizer and BioNTech sayThe third shot appears to broaden the ability of the immune system to recognize variants such as omicron.
続きを読む »